Associate Professor at @HopkinsMedicine; PhD; Science of psychedelics and other altered states of consciousness @TheYadenLab @JHPsychedelics @psychedelethics
Johns Hopkins University
Joined February 2009
- Tweets10.2K
- Following797
- Followers7.3K
- Likes25.8K
Pinned Tweet
Is the psychedelic hype bubble about to burst?
Might that be best for the field?
In a new @JAMAPsych article w/ me, @jpotash1, & R. Griffiths, we argue for moving beyond overly negative AND positive extremes to embrace the actual evidence
@JHPsychedelics
jamanetwork.com/journals/jam…
David B. Yaden retweeted
As psychedelic treatments approach potential FDA approval, psychiatrists need to be ready for patients’ questions.
To help prepare them, Johns Hopkins, Yale, NYU, and Columbia developed a standardized psychedelic medicine curriculum for psychiatry trainees. The first multi-site evaluation of the course was just published in Academic Psychiatry.
After the course:
💡 Confidence counseling patients about clinical research and legal care nearly doubled
🔬 Understanding of the limitations of current evidence rose sharply
📈 Knowledge quiz scores improved
⚖️ Trainees gained a more balanced, critically informed view of the evidence, without inflated enthusiasm for the field
We’re continuing to develop educational and training programs for professionals across a range of fields, so stay tuned!
doi.org/10.1007/s40596-026-0…
David B. Yaden retweeted
New paper 🚨The Need to Clarify Regulation of Mental Health Artificial Intelligence | JAMA Psychiatry. Led by Will Smith
David B. Yaden retweeted
doi.org/10.1007/s12152-026-0…
Beyond excited to announce this piece just published in @NeuroethicsJ!
During my research year at @JHPsychedelics, I had the privilege to co-facilitate prep, dosing and integration sessions for a number of participants in one of the psilocybin trials
David B. Yaden retweeted
Are psychedelics anti-inflammatory!?
I am beyond excited to present the first systematic review and meta-analysis of the immunomodulatory effects of serotonergic psychedelics!
sciencedirect.com/science/ar…
David B. Yaden retweeted
New paper in JME Practical Bioethics: Katherine Cheung @Katherine_Chg, Edward Jacobs @eddietalksdrugs, and David Yaden @ExistWell review the ethics of psychedelic clinical trials and flag key concerns to resolve as psychedelics move toward real-world care.
jmepb.bmj.com/content/2/4/e0…
David B. Yaden retweeted
The Paul Meehl Graduate School Symposium is kicking off with a keynote by the Best Thesis Award winner Charlotte Rulkens on the role of replications in the Humanities, studying the repetition of art attribution.
David B. Yaden retweeted
This is huge!! @NIMHDirector will allocate $$$ to fund, essentially, clinical trial networks for #psychedelics and other rapidly-acting psychoactives (#ketamine #mdma )
grants.nih.gov/grants/guide/…
A comprehensive review of bioethical progress and need for further work on psychedelic research and potential clinical applications across screening, informed consent, dosing, follow-up, & more. Work led by @Katherine_Chg w/ @eddietalksdrugs and me. Check out the thread and link:
A growing body of bioethical work has examined ethical issues related to the use of psychedelics in clinical research. With @eddietalksdrugs and @ExistWell, we try to take stock in our state-of-the-field review, published in JME Practical Bioethics.
David B. Yaden retweeted
We organize the literature here by trial stage (e.g. screening, informed consent, dosing, follow-up), in addition to identifying cross-cutting concerns.
David B. Yaden retweeted
A growing body of bioethical work has examined ethical issues related to the use of psychedelics in clinical research. With @eddietalksdrugs and @ExistWell, we try to take stock in our state-of-the-field review, published in JME Practical Bioethics.
Psychedelics are such a common subject of discussion in medical and clinical contexts, that an understanding of the state of science is useful for any clinician. Here is a way to learn about psychedelic science and medicine:
What should clinicians know about psychedelic-assisted treatments? Learn from our experts and earn 6.5 CME/CE credits! 🔗 ⬇️
Fri, Oct. 9th | Online | 8:45am-4:30pm ET
hopkinscme.cloud-cme.com/cou…
Psychedelics are a common subject in medical and clinical contexts these days. This CME course provides an overview of the scientific state of the evidence. It is led by clinicians and scientists at @JHPsychedelics and one of the most efficient ways to get a sense for the field:
Just 2 days away from our online CME/CE course on psychedelic-assisted treatments, taught by our clinicians and expert scientists! Join us on Friday, Oct 9th from 8:45am-4:30pm ET. More info and registration link below! hopkinscme.cloud-cme.com/cou…
David B. Yaden retweeted
Just 2 days away from our online CME/CE course on psychedelic-assisted treatments, taught by our clinicians and expert scientists! Join us on Friday, Oct 9th from 8:45am-4:30pm ET. More info and registration link below! hopkinscme.cloud-cme.com/cou…
David B. Yaden retweeted
This one has been a long time coming - along with optogenetics, chemogenetics and the development of powerful sensors have been game changers for neuroscience.
BREAKING NEWS
The 2026 #NobelPrize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics.”
David B. Yaden retweeted
Had a great time helping represent @TheYadenLab and @JHPsychedelics yesterday at the @FDA's public hearing on psychedelics' therapeutic potential -- big things on the horizon
Representing @TheYadenLab at @JHPsychedelics & @psychedelethics at @FDA. Postdoc Eddie Jacobs @eddietalksdrugs spoke to how the evidence on psychedelic treatments comes from clinical trials, so those safeguards should be used for initial roll-out, to be adjusted based on data…
David B. Yaden retweeted
The first completely on-site preclinical animal study from @JHPsychedelics.
An immensely valuable collaboration with Division of Behavioral Biology. So grateful that I got to lead it and work with what can only be called the dream team!
Unroll the tweet below for deets 📜
New paper led by @PraachiTiwari, a former postdoc in @TheYadenLab, now faculty at Div of Behavioral Bio & @JHPsychedelics (also w/ @CassieMoorePhD, Brian Jenkins, Elise Weerts, me).
We examined how psilocybin affects a broader range of spontaneous behaviors in rats than HTR...
David B. Yaden retweeted
1) In terms of safety, the prevalence of serious medical and psychiatric issues was quite low, although qualified by concerns about the high bar that needs to be achieved for reporting to occur
David B. Yaden retweeted
Trial safety data won't transfer cleanly to routine care, and we can't with confidence know which safeguards contribute to it. Record how clinics vary in practice, collect evidence of outcomes, and specify review points and evidential thresholds for loosening safeguards
David B. Yaden retweeted
Calling faculty interested in the future of psychedelic medicine:
If you’re full-time faculty in nursing, social work, medicine, psychology, counseling, PA education, or public health, and want to deepen your engagement with the rapidly evolving field of psychedelic therapy, consider applying for this fellowship.
Please share with someone who should be in the room. Application link below.
